Prevail Therapeutics is a biotech company that develops gene therapies for Parkinson’s disease and other neurodegenerative diseases. The company was founded in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed. Prevail Therapeutics is headquartered in New York and aims to slow or stop the neurodegenerative process by developing AAV-based gene therapies. The company's pipeline includes PR001, PR006, and PR004, and they follow a precision medicine approach to target patient populations with urgent unmet needs. In January 2021, Prevail Therapeutics was acquired by Eli Lilly and Company and is now a wholly owned subsidiary. Prevail Therapeutics is building a team of dedicated individuals who share their passion for serving patients with neurodegenerative diseases.